SMi’s 5th conference on Drug Safety 2018

157

The Global Pharmaceutical Market currently has a market value of $1057 billion. If a drug is found to be unsafe, causing serious side effects, it can have a huge knock on effect on revenue, causing huge losses to pharmaceutical companies manufacturing the drug.

Drug Safety 2018 aims to discuss the latest findings and current thinking on pharmacovigilance. Importantly, it will address the newest regulatory updates and interpretations of them, including the impact of the vital and much awaited Clinical Trial Regulations. Hear from industry experts this June, with the likes of Pfizer, MHRA, Sanofi, Takeda, Novo Nordisk, Amgen and many more.

For drugs anywhere, it’s the safety in patients which is a huge issue constantly under surveillance, irrespective of where the drug is in its pipeline.

Day 1 Opening Keynote Presentation – ‘Risk Management of Medicines in Pregnancy – From Thalidomide to Valproate.’

The opening keynote presentation on day 1 will be presented by David Lewis, who is the Senior Adviser of Pharmacovigilance, CMO Patient Safety, at Novartis and also the Senior Visiting Research Fellow, Department of Pharmacy, Pharmacology & Postgraduate Medicine, at the University of Hertfordshire.

There has been a lack of systematic research to understand the adverse effects of exposure to medicinal products during pregnancy in humans. This constitutes a growing safety concern, illustrated by the first public hearing held by the EMA (on valproate-containing medicines). The challenge spans the lifecycle of medicines from discovery to general sales. New tools and techniques need to be developed and brought in to operation to improve risk minimization and protect public health.

PLUS… An Interactive Half-Day Post-Conference Workshop:

Workshop: PASS: Evaluation of Risk Minimisation

Workshop Leader: Nawab Qizilbash, Head, OXON Epidemiology and Honorary Associate Professor, London School of Hygiene & Tropical Medicine

Brief Overview: Learn about risk minimisation in Europe: its implementation, evaluation and PRAC expectations.

For those looking to attend there are currently early-bird rates available up to £400, for a limited time only!

Further information and the complete agenda is available at: www.drugsafetyconference.co.uk/prmktg

SMi presents the 5th conference on:

Drug Safety 2018

Date: 11th – 12th June 2018

Workshops: 13th June 2018

Location: Holiday Inn Kensington Forum, London UK

Website: www.drugsafetyconference.co.uk/prmktg

 

 

Contact Information:

For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk